Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90d41c5c08b4cc27008c8d448154a71f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2827 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5f53dd90b89819d0bd6bb33a1c15918 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1278fefd6e835e8cb70fae09daa446be http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97710ffda9064bfdfbafb080a301fa34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d434b674a74ab84d6ce00b5a2f4bcb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa535ba76e99a0c3ff391e19eefa734c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b098f33a11b238f436d9a3204ca68c0c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff17cd9a7d7e677c88cbf0c11d1434d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2af44d1caf6e417928c48627305232ba |
publicationDate |
2022-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2022273809-A1 |
titleOfInvention |
Axl antibody-drug conjugates for use in treating cancer |
abstract |
The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl. |
priorityDate |
2019-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |